Effective September 18, 2019, X4 Pharmaceuticals, Inc. appointed William E. Aliski as a Class II director to serve for the term expiring at the Company’s 2022 Annual Meeting of Stockholders or until his earlier death, resignation or removal. In connection therewith, the Board of Directors (the “Board”) of the Company increased the authorized number of directors to seven. Mr. Aliski has not been appointed to any committees of the Board at this time. Since 2011, Mr. Aliski has served as an independent consultant to life sciences companies focused on orphan diseases, with particular focus on commercial strategy, market access, pricing, and reimbursement.